Abstract
Because of the necessary immunodepletion prior to cord blood transplantation as well as the immaturity of cord blood immune cells, recipients experience a high incidence of viral infection in addition to complications observed after hematopoietic stem cell transplantation, such as relapse and graft-versus-host disease. We describe current immunotherapeutic approaches to treating these complications, including the generation of antigen-specific T cells from cord blood, redirecting cord blood T cells using chimeric antigen receptors, and generating cord blood-derived natural killer cells and regulatory T cells.
MeSH terms
-
Cord Blood Stem Cell Transplantation* / adverse effects
-
Fetal Blood / cytology
-
Graft vs Host Disease / etiology
-
Graft vs Host Disease / immunology
-
Graft vs Host Disease / therapy*
-
Humans
-
Immunotherapy, Adoptive*
-
Killer Cells, Natural / immunology
-
Receptors, Antigen, T-Cell / genetics
-
Receptors, Antigen, T-Cell / metabolism
-
Recombinant Fusion Proteins / genetics
-
T-Lymphocyte Subsets / cytology
-
T-Lymphocyte Subsets / immunology
-
T-Lymphocyte Subsets / metabolism
-
T-Lymphocytes, Regulatory / cytology
-
T-Lymphocytes, Regulatory / immunology
-
T-Lymphocytes, Regulatory / metabolism
-
Transplantation Conditioning* / adverse effects
-
Virus Diseases / etiology
-
Virus Diseases / immunology
-
Virus Diseases / therapy*
Substances
-
Receptors, Antigen, T-Cell
-
Recombinant Fusion Proteins